openPR Logo
Press release

Acute Respiratory Distress Syndrome Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | RS BioTherapeutics, AVM Biotech, Cynata Therapeutics

05-09-2025 03:26 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Acute Respiratory Distress Syndrome Pipeline 2025: Key

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Respiratory Distress Syndrome pipeline constitutes 50+ key companies continuously working towards developing 50+ Acute Respiratory Distress Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Acute Respiratory Distress Syndrome Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome Market.

Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years.

*
Acute Respiratory Distress Syndrome companies working in the treatment market are RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompe Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy's and St Thomas' NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment

*
Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years.

*
In February 2025, Bonus Biogroup (TASE: BONS), a late-stage biotech firm specializing in immunomodulatory and regenerative mesenchymal stromal cell (MSC) therapies, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial in the U.S. The study will assess the safety and effectiveness of MesenCure Trademark -an allogeneic cell therapy composed of enhanced MSCs derived from adipose tissue-for the treatment of respiratory distress in severely ill, hospitalized patients suffering from COVID-19-related pneumonia. MesenCure is designed to address inflammation and tissue damage.

*
In January 2025, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapies targeting the complement system, has announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC Registered (vilobelimab). This approval covers the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard care and require invasive mechanical ventilation (IMV), with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC is the first and only approved therapy in the EU specifically for SARS-CoV-2-related ARDS.

*
In November 2024, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm specializing in anti-inflammatory treatments targeting the complement system, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the marketing authorization of GOHIBIC (vilobelimab). The recommendation supports its use under exceptional circumstances for adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids and invasive mechanical ventilation (IMV), with or without ECMO. The company anticipates a final decision from the European Commission within 67 days.

*
In October 2024, BioAegis Therapeutics, an innovative biotech company focused on developing therapies for inflammatory diseases, is excited to announce the enrollment of the first patient in its Phase 2 study of rhu-pGSN for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955).

Acute Respiratory Distress Syndrome Overview

Acute Respiratory Distress Syndrome (ARDS) is a severe condition in which the lungs become inflamed and fill with fluid, leading to difficulty breathing and low oxygen levels in the blood. It can result from various causes, including infections, trauma, pneumonia, or inhalation of harmful substances. Symptoms include shortness of breath, rapid breathing, and low oxygen levels. ARDS is a medical emergency that often requires hospitalization, with treatments including oxygen therapy, mechanical ventilation, and addressing the underlying cause. In severe cases, ARDS can lead to organ failure and may be life-threatening.

Get a Free Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight [https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Acute Respiratory Distress Syndrome Drugs Under Different Phases of Clinical Development Include:

*
RSBT-001: RS BioTherapeutics

*
AVM0703: AVM Biotechnology

*
CYP 001: Cynata Therapeutics

*
AV 001: Vasomune Therapeutics

*
ALT-100: Aqualung Therapeutics

*
STSA-1002: Staidson (Beijing) Biopharmaceuticals

*
GEn-1124: GEn1E Lifesciences

*
Descartes 30: Cartesian Therapeutics

*
Rhu-pGSN: BioAegis Therapeutics Inc.

*
ExoFlo: Direct Biologics, LLC

*
Reparixin 600mg: Dompe Farmaceutici S.p.A

*
Centhaquine: Pharmazz, Inc.

*
ALT-100 mAb: Aqualung Therapeutics Corp.

*
MRG-001: MedRegen LLC

*
TTI-0102: Thiogenesis Therapeutics, Inc.

*
Dexamethasone: Hospital Universitario Infanta Leonor

*
Isoflurane: Guy's and St Thomas' NHS Foundation Trust

*
Pirfenidone/Placebo: Fujian Medical University

*
Trimodulin: Biotest

*
AeroFact: Aerogen Pharma Limited

*
Ibudilast: MediciNova

*
Poractant Alfa: NorthShore University HealthSystem

*
Tozorakimab: AstraZeneca

*
L-citrulline: Asklepion Pharmaceuticals

Acute Respiratory Distress Syndrome Route of Administration

Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravitreal

*
Subretinal

*
Topical

*
Molecule Type

Acute Respiratory Distress Syndrome Molecule Type

Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

*
Product Type

Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment

*
Acute Respiratory Distress Syndrome Assessment by Product Type

*
Acute Respiratory Distress Syndrome By Stage and Product Type

*
Acute Respiratory Distress Syndrome Assessment by Route of Administration

*
Acute Respiratory Distress Syndrome By Stage and Route of Administration

*
Acute Respiratory Distress Syndrome Assessment by Molecule Type

*
Acute Respiratory Distress Syndrome by Stage and Molecule Type

DelveInsight's Acute Respiratory Distress Syndrome Report covers around 50+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Acute Respiratory Distress Syndrome product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Acute Respiratory Distress Syndrome Therapeutics Market include:

Key companies developing therapies for Acute Respiratory Distress Syndrome are - Fisher & Paykel Healthcare Limited, NRx Pharmaceuticals, Inc., Faron Pharmaceuticals, BioMarck Pharmaceuticals, GE Healthcare, Hamilton Company, Athersys, United Therapeutics, Apeptico Forschung, HEALIOS K.K, Dragerwerk AG & Co. KGaA, ALung Technologies, Inc ( LivaNova PLC), and others.

Acute Respiratory Distress Syndrome Pipeline Analysis:

The Acute Respiratory Distress Syndrome pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment.

*
Acute Respiratory Distress Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Respiratory Distress Syndrome drugs and therapies [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acute Respiratory Distress Syndrome Pipeline Market Drivers

*
Rising incidence of Acute Respiratory Distress Syndrome, the rising geriatric population are some of the important factors that are fueling the Acute Respiratory Distress Syndrome Market.

Acute Respiratory Distress Syndrome Pipeline Market Barriers

*
However, increasing Cost of Treatment Therapeutics, lack of Skilled Professionals and other factors are creating obstacles in the Acute Respiratory Distress Syndrome Market growth.

Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight

*
Coverage: Global

*
Key Acute Respiratory Distress Syndrome Companies: RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompe Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy's and St Thomas' NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others

*
Key Acute Respiratory Distress Syndrome Therapies: RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others

*
Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies

*
Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers

Request for Sample PDF Report for Acute Respiratory Distress Syndrome Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Acute Respiratory Distress Syndrome Report Introduction

2. Acute Respiratory Distress Syndrome Executive Summary

3. Acute Respiratory Distress Syndrome Overview

4. Acute Respiratory Distress Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Acute Respiratory Distress Syndrome Pipeline Therapeutics

6. Acute Respiratory Distress Syndrome Late Stage Products (Phase II/III)

7. Acute Respiratory Distress Syndrome Mid Stage Products (Phase II)

8. Acute Respiratory Distress Syndrome Early Stage Products (Phase I)

9. Acute Respiratory Distress Syndrome Preclinical Stage Products

10. Acute Respiratory Distress Syndrome Therapeutics Assessment

11. Acute Respiratory Distress Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Respiratory Distress Syndrome Key Companies

14. Acute Respiratory Distress Syndrome Key Products

15. Acute Respiratory Distress Syndrome Unmet Needs

16 . Acute Respiratory Distress Syndrome Market Drivers and Barriers

17. Acute Respiratory Distress Syndrome Future Perspectives and Conclusion

18. Acute Respiratory Distress Syndrome Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-respiratory-distress-syndrome-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-rs-biotherapeutics-avm-biotech-cynata-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Respiratory Distress Syndrome Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | RS BioTherapeutics, AVM Biotech, Cynata Therapeutics here

News-ID: 4008396 • Views:

More Releases from ABNewswire

Avanti Rides Debuts in Southern Florida, Transforming How Drivers and Passengers Connect
Avanti Rides Debuts in Southern Florida, Transforming How Drivers and Passengers …
Miami, FL - Avanti Rides introduces a new chapter in ride-hailing by combining passenger safety, driver empowerment, and seamless technology into a single app. Designed for the evolving needs of both drivers and riders, Avanti is delivering smarter bookings, stronger protection, and unmatched flexibility. Built for Drivers Who Want More Than Just Rides Avanti Rides recognizes that drivers are the foundation of the platform and offers a range of benefits focused on
UVS-IT Unveils Guide to Choosing the Best Managed IT Services in Atlanta
UVS-IT Unveils Guide to Choosing the Best Managed IT Services in Atlanta
Hey there, Atlanta business warriors! Have you ever felt that picking the perfect Managed IT Service is a bit like choosing the ultimate wingman for your company's tech needs? Trust me, it's not just a matter of finding someone who looks good on paper. With technology increasingly steering the ship of our businesses, selecting a reliable Managed IT Service is becoming as crucial as that morning cup of coffee we
3D-Engineering: How 3D Scanning Services Are Revolutionizing Modern Engineering Projects
3D-Engineering: How 3D Scanning Services Are Revolutionizing Modern Engineering …
Imagine being able to capture every nook and cranny of an object down to the most intricate detail. Sounds magical, right? That's the power of 3D scanning services [https://3d-engineering.net/engineering-services/3d-laser-scanning-services/] in today's engineering projects. Across industries, from automotive and construction to aerospace and healthcare, 3D scanning is transforming how things are measured, mapped, and made. Whether you're designing a new building or manufacturing precision components, 3D scanning takes you from the
SLCLawyer: How a Separation Agreement Can Help Couples Save Thousands in Legal Fees
SLCLawyer: How a Separation Agreement Can Help Couples Save Thousands in Legal F …
Image: https://www.abnewswire.com/upload/2025/10/7d762be2535d9a3c2274975ea0a87869.jpg When John and Mary decided to separate after 12 years of marriage, they thought they could handle it on their own. Money was tight, emotions were high, and the internet offered dozens of free and cheap separation agreement templates. They downloaded one, filled in the blanks, and signed it at the kitchen table. At first, it seemed like a practical solution. They avoided paying lawyers, saved a few hundred dollars,

All 5 Releases


More Releases for Acute

Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth